ASCO 2019

CytImmune is excited to announce that our collaborative work with the US National Cancer Institute has resulted in an ASCO abstract. ASCO Submission Category Developmental Therapeutics and Tumor Biology (Nonimmuno), New Targets and New Technologies Authors and Institutions Naris Nilubol, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, MD 208921 David Oarr and Lawrence Tamarkin, …

Aurimune-TNF and T-Cells: A Surprising Result

T-Cells are all the rage these days, and with good reason. It’s hard to find an academic laboratory or big pharma company that isn’t throwing their lot behind a PDL-1 or CAR-T technology of one type or another. CytImmune is not heading down that path, but since immunotherapy in most of its current forms is…

Mouse Models used in Cancer Research

Cancer is a highly researched disease. Thousands of mouse studies are published every year, and cancer patients are inundated with headlines claiming breakthroughs and promising discoveries. To understand the context of these reported data, you need to know the mouse model used in the experiments. This information is often not included in main stream publications,…

Shooting for 95%

We have created a nanotechnology based cancer therapy that we believe is capable of delivering a 95% response rate to patients of some solid tumor cancers. Why are we so confident? Because it has already been done. SOME BACKGROUND A characteristic of the micro-environment in all solid tumors, and a primary driver of cancer therapy…

The Tumor Micro Environment is Under a lot of Pressure

      The tumor micro-environment is a hot topic these days. I suspect it has a lot to do with the rise of immunotherapy and the delta in performance of CAR-T therapies between hematological cancers versus solid tumors, which represent the majority of cancers. This year’s AACR meeting is producing more than a few…

Has nanotechnology failed cancer patients?

Negative news abounded for cancer based nanotechnologies in 2016. From the outside, it might appear that its promise has faded. The reality is far from the truth. Like many great endeavors, past failures are shining a bright light on the path forward.